CORT

insider transactions

CORCEPT THERAPEUTICS INC — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

Net shares · 30d

-247.8K

0 buy · 247.8K sell

Net value · 30d

-$17.9M

$0 in · $17.9M out

Sentiment · 30d

Net selling

0% buying · 100% selling

Open-market trades · 30d

0 buy · 247.8K sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Sell·S
Jun 17, 26

David L Mahoney

Director

$1.7M

20.0K sh · $84.53

Own -43%
Sell·S
Jun 16, 26

James N Wilson

Director · 10b5-1

$486.6K

5.8K sh · $83.57

Own -1%
Sell·S
Jun 16, 26

James N Wilson

Director · 10b5-1

$345.4K

4.2K sh · $82.69

Own -0%
Exercise·M
Jun 15, 26

Atabak Mokari KEY

Chief Financial Officer · 10b5-1

$0

40.0K sh

Own New
Sell·S
Jun 15, 26

Atabak Mokari KEY

Chief Financial Officer · 10b5-1

$165

2 sh · $82.45

Own -0%
Sell·S
Jun 15, 26

Atabak Mokari KEY

Chief Financial Officer · 10b5-1

$1.6M

19.5K sh · $81.81

Own -55%
Sell·S
Jun 15, 26

Atabak Mokari KEY

Chief Financial Officer · 10b5-1

$896.9K

11.1K sh · $80.94

Own -24%
Sell·S
Jun 15, 26

Atabak Mokari KEY

Chief Financial Officer · 10b5-1

$754.9K

9.4K sh · $80.02

Own -17%
Exercise·M
Jun 15, 26

Atabak Mokari KEY

Chief Financial Officer · 10b5-1

$770.4K

40.0K sh · $19.26

Own +248%
Other·F
Jun 2, 26

Joseph Douglas Lyon

Chief Accounting & Technology…

$18.9K

269 sh · $70.44

Own -4%
Other·F
Jun 2, 26

Sean Maduck KEY

President, Corcept Endocrinol… · 10b5-1

$31.8K

452 sh · $70.44

Own -4%
Other·F
Jun 2, 26

Atabak Mokari KEY

Chief Financial Officer · 10b5-1

$27.8K

395 sh · $70.44

Own -2%
Other·F
Jun 2, 26

Gary Charles Robb

Chief Business Officer

$25.2K

358 sh · $70.44

Own -1%
Exercise·M
Jun 2, 26

William Guyer

Chief Development Officer · 10b5-1

$0

20.0K sh

Own +15%
Sell·S
Jun 2, 26

William Guyer

Chief Development Officer · 10b5-1

$1.4M

20.0K sh · $70.60

Own -83%
Exercise·M
Jun 2, 26

William Guyer

Chief Development Officer · 10b5-1

$433.0K

20.0K sh · $21.65

Own +502%
Sell·S
Jun 1, 26

Joseph K Belanoff KEY

Chief Executive Officer · 10b5-1

$895.3K

12.8K sh · $69.74

Own -0%
Grant·A
Jun 1, 26

Joseph Douglas Lyon

Chief Accounting & Technology…

$0

537 sh

Own +8%
Grant·A
Jun 1, 26

Joseph Douglas Lyon

Chief Accounting & Technology…

$37.8K

537 sh · $70.44

Own +9%
Grant·A
Jun 1, 26

William Guyer

Chief Development Officer

$0

877 sh

Own +28%
Grant·A
Jun 1, 26

William Guyer

Chief Development Officer

$61.8K

877 sh · $70.44

Own +39%
Exercise·M
Jun 1, 26

Sean Maduck KEY

President, Corcept Endocrinol… · 10b5-1

$0

25.0K sh

Own +21%
Grant·A
Jun 1, 26

Sean Maduck KEY

President, Corcept Endocrinol… · 10b5-1

$0

615 sh

Own +6%
Grant·A
Jun 1, 26

Sean Maduck KEY

President, Corcept Endocrinol… · 10b5-1

$43.3K

615 sh · $70.44

Own +7%
Sell·S
Jun 1, 26

Sean Maduck KEY

President, Corcept Endocrinol… · 10b5-1

$278.1K

3.9K sh · $70.75

Own -30%
Sell·S
Jun 1, 26

Sean Maduck KEY

President, Corcept Endocrinol… · 10b5-1

$1.5M

21.1K sh · $70.11

Own -62%
Exercise·M
Jun 1, 26

Sean Maduck KEY

President, Corcept Endocrinol… · 10b5-1

$206.8K

25.0K sh · $8.27

Own +278%
Exercise·M
Jun 1, 26

Atabak Mokari KEY

Chief Financial Officer · 10b5-1

$0

40.0K sh

Own +200%
Grant·A
Jun 1, 26

Atabak Mokari KEY

Chief Financial Officer · 10b5-1

$0

634 sh

Own +4%
Grant·A
Jun 1, 26

Atabak Mokari KEY

Chief Financial Officer · 10b5-1

$44.7K

634 sh · $70.44

Own +4%
Sell·S
Jun 1, 26

Atabak Mokari KEY

Chief Financial Officer · 10b5-1

$2.8M

40.0K sh · $70.00

Own -72%
Exercise·M
Jun 1, 26

Atabak Mokari KEY

Chief Financial Officer · 10b5-1

$770.4K

40.0K sh · $19.26

Own +262%
Grant·A
Jun 1, 26

Gary Charles Robb

Chief Business Officer

$0

776 sh

Own +3%
Grant·A
Jun 1, 26

Gary Charles Robb

Chief Business Officer

$54.7K

776 sh · $70.44

Own +3%
Other·G
May 29, 26

Joseph K Belanoff KEY

Chief Executive Officer · 10b5-1

$0

150.0K sh

Own -50%
Other·G
May 29, 26

Joseph K Belanoff KEY

Chief Executive Officer · 10b5-1

$0

300.0K sh

Own -10%
Sell·S
May 27, 26

Joseph Douglas Lyon

Chief Accounting & Technology…

$325.0K

5.0K sh · $65.00

Own -45%
Exercise·M
May 27, 26

Sean Maduck KEY

President, Corcept Endocrinol… · 10b5-1

$0

75.0K sh

Own +82%
Sell·S
May 27, 26

Sean Maduck KEY

President, Corcept Endocrinol… · 10b5-1

$1.4M

20.4K sh · $66.16

Own -69%
Sell·S
May 27, 26

Sean Maduck KEY

President, Corcept Endocrinol… · 10b5-1

$3.6M

54.6K sh · $65.37

Own -65%
Exercise·M
May 27, 26

Sean Maduck KEY

President, Corcept Endocrinol… · 10b5-1

$620.2K

75.0K sh · $8.27

Own +835%
Other·G
May 27, 26

James N Wilson

Director

$0

9.0K sh

Own -100%
Other·G
May 27, 26

James N Wilson

Director

$0

892.1K sh

Own -99%

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
Jun 17, 2026	David L Mahoney	Director	Sell S	20.0K	-43%	$84.53	$1.7M
Jun 16, 2026	James N Wilson 10b5-1	Director	Sell S	5.8K	-1%	$83.57	$486.6K
Jun 16, 2026	James N Wilson 10b5-1	Director	Sell S	4.2K	-0%	$82.69	$345.4K
Jun 15, 2026	Atabak Mokari KEY 10b5-1	Chief Financial Officer	Exercise M	40.0K	New	—	$0
Jun 15, 2026	Atabak Mokari KEY 10b5-1	Chief Financial Officer	Sell S	2	-0%	$82.45	$165
Jun 15, 2026	Atabak Mokari KEY 10b5-1	Chief Financial Officer	Sell S	19.5K	-55%	$81.81	$1.6M
Jun 15, 2026	Atabak Mokari KEY 10b5-1	Chief Financial Officer	Sell S	11.1K	-24%	$80.94	$896.9K
Jun 15, 2026	Atabak Mokari KEY 10b5-1	Chief Financial Officer	Sell S	9.4K	-17%	$80.02	$754.9K
Jun 15, 2026	Atabak Mokari KEY 10b5-1	Chief Financial Officer	Exercise M	40.0K	+248%	$19.26	$770.4K
Jun 2, 2026	Joseph Douglas Lyon	Chief Accounting & Technology Officer	Other F	269	-4%	$70.44	$18.9K
Jun 2, 2026	Sean Maduck KEY 10b5-1	President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.	Other F	452	-4%	$70.44	$31.8K
Jun 2, 2026	Atabak Mokari KEY 10b5-1	Chief Financial Officer	Other F	395	-2%	$70.44	$27.8K
Jun 2, 2026	Gary Charles Robb	Chief Business Officer	Other F	358	-1%	$70.44	$25.2K
Jun 2, 2026	William Guyer 10b5-1	Chief Development Officer	Exercise M	20.0K	+15%	—	$0
Jun 2, 2026	William Guyer 10b5-1	Chief Development Officer	Sell S	20.0K	-83%	$70.60	$1.4M
Jun 2, 2026	William Guyer 10b5-1	Chief Development Officer	Exercise M	20.0K	+502%	$21.65	$433.0K
Jun 1, 2026	Joseph K Belanoff KEY 10b5-1	Chief Executive Officer	Sell S	12.8K	-0%	$69.74	$895.3K
Jun 1, 2026	Joseph Douglas Lyon	Chief Accounting & Technology Officer	Grant A	537	+8%	—	$0
Jun 1, 2026	Joseph Douglas Lyon	Chief Accounting & Technology Officer	Grant A	537	+9%	$70.44	$37.8K
Jun 1, 2026	William Guyer	Chief Development Officer	Grant A	877	+28%	—	$0
Jun 1, 2026	William Guyer	Chief Development Officer	Grant A	877	+39%	$70.44	$61.8K
Jun 1, 2026	Sean Maduck KEY 10b5-1	President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.	Exercise M	25.0K	+21%	—	$0
Jun 1, 2026	Sean Maduck KEY 10b5-1	President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.	Grant A	615	+6%	—	$0
Jun 1, 2026	Sean Maduck KEY 10b5-1	President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.	Grant A	615	+7%	$70.44	$43.3K
Jun 1, 2026	Sean Maduck KEY 10b5-1	President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.	Sell S	3.9K	-30%	$70.75	$278.1K
Jun 1, 2026	Sean Maduck KEY 10b5-1	President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.	Sell S	21.1K	-62%	$70.11	$1.5M
Jun 1, 2026	Sean Maduck KEY 10b5-1	President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.	Exercise M	25.0K	+278%	$8.27	$206.8K
Jun 1, 2026	Atabak Mokari KEY 10b5-1	Chief Financial Officer	Exercise M	40.0K	+200%	—	$0
Jun 1, 2026	Atabak Mokari KEY 10b5-1	Chief Financial Officer	Grant A	634	+4%	—	$0
Jun 1, 2026	Atabak Mokari KEY 10b5-1	Chief Financial Officer	Grant A	634	+4%	$70.44	$44.7K
Jun 1, 2026	Atabak Mokari KEY 10b5-1	Chief Financial Officer	Sell S	40.0K	-72%	$70.00	$2.8M
Jun 1, 2026	Atabak Mokari KEY 10b5-1	Chief Financial Officer	Exercise M	40.0K	+262%	$19.26	$770.4K
Jun 1, 2026	Gary Charles Robb	Chief Business Officer	Grant A	776	+3%	—	$0
Jun 1, 2026	Gary Charles Robb	Chief Business Officer	Grant A	776	+3%	$70.44	$54.7K
May 29, 2026	Joseph K Belanoff KEY 10b5-1	Chief Executive Officer	Other G	150.0K	-50%	—	$0
May 29, 2026	Joseph K Belanoff KEY 10b5-1	Chief Executive Officer	Other G	300.0K	-10%	—	$0
May 27, 2026	Joseph Douglas Lyon	Chief Accounting & Technology Officer	Sell S	5.0K	-45%	$65.00	$325.0K
May 27, 2026	Sean Maduck KEY 10b5-1	President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.	Exercise M	75.0K	+82%	—	$0
May 27, 2026	Sean Maduck KEY 10b5-1	President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.	Sell S	20.4K	-69%	$66.16	$1.4M
May 27, 2026	Sean Maduck KEY 10b5-1	President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.	Sell S	54.6K	-65%	$65.37	$3.6M
May 27, 2026	Sean Maduck KEY 10b5-1	President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.	Exercise M	75.0K	+835%	$8.27	$620.2K
May 27, 2026	James N Wilson	Director	Other G	9.0K	-100%	—	$0
May 27, 2026	James N Wilson	Director	Other G	892.1K	-99%	—	$0

About CORT insider trading

This page tracks insider transactions for CORCEPT THERAPEUTICS INC (CORT) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.